FDA Clinical Trials

Our medicines will transform lives

Following its inception, MMJ is positioned to commenced its first clinical trials evaluating different cannabinoid formulations as potential therapeutics with an initial focus on the development of an gel cap formulation with two principal cannabinoid components, cannabidiol (CBD) and delta-9 tetrahydrocannabinol (THC).

Working with leading cannabinoid scientists around the world, MMJ is continuing to explore the potential of a range of novel cannabinoid and other botanical molecules in a number of distinct therapeutic areas.

MMJ’s lead product candidate, is a liquid formulation of highly purified CBD/THC being investigated for severe neurological disorders. This product is the result of extensive research. In 2019, MMJ will commence an orphan clinical program in Multiple Sclerosis and Huntington’s disease to treat forms of spasticity and chorea.

MMJ has submitted an Investigational New Drug Application with the FDA and has applied to the FDA for Orphan Drug Designation for the treatment of several chronic diseases. Additionally, MMJ is hoping to achieve Fast Track Designation from the FDA for the treatment of MS. MMJ’s focus is to bring novel natural botanical plant and cannabinoid-based prescription medicines to market as pharmaceuticals. These goals will be accomplished by implementing rapid cost-effective product development plans that addresses patient’s unmet needs.